# A Study to Investigate Subcutaneous Isatuximab in Combination With Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory

Source: https://onco.cc/trials/nct05704049/  
OnCo record `nct05704049` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Isatuximab, Carfilzomib, Dexamethasone in multiple myeloma, run by Sanofi, active and no longer recruiting.

## Summary

A Study to Investigate Subcutaneous Isatuximab in Combination With Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma is a phase 2 interventional study registered as NCT05704049 by Sanofi, with 118 participants enrolled, started 2023-04-05 and due to reach its primary completion in 2025-12-22. Interventions recorded: Isatuximab, Carfilzomib, Dexamethasone, Dexamethasone IV, Montelukast. Conditions listed: Relapsed/Refractory Multiple Myeloma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT05704049
- Phase: 2
- Setting: A Randomized, Phase 2, Open Label Study Evaluating Subcutaneous Administration of Isatuximab in Combination With Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM)
- Sponsor: Sanofi
- Enrolled: 118

## Sources

- ClinicalTrials.gov NCT05704049: https://clinicaltrials.gov/study/NCT05704049

## Connected records

- cancers: [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/)
- drugs: [Carfilzomib](https://onco.cc/drugs/carfilzomib/), [Dexamethasone](https://onco.cc/drugs/dexamethasone/), [Isatuximab](https://onco.cc/drugs/isatuximab/)
- companies: [Sanofi](https://onco.cc/companies/sanofi/)

---
JSON: https://onco.cc/api/v1/entities/nct05704049.json